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A close relationship exists between systemic inflammation
and thrombosis, so that patients with autoimmune diseases
may have an increased risk of thrombosis.1 The major com-
ponents involved in the pathogenesis of thrombosis are
endothelial damage, coagulation cascade activation, fibrino-
lytic system impairment, platelet activation, and blood flow
alterations. However, the immune system may be also in-
volved in the thrombotic process, and inflammation is a
crucial thrombogenic factor.2,3 The coagulation system inter-
actswith the inflammatory pathway, leading to the activation
of immune cells, as leukocytes and macrophages. The pro-
duction of proinflammatory cytokines and chemokines may
stimulate and modulate endothelial function and blood
coagulation.4
Several autoimmune disorders are characterized by an
increased risk of cardiovascular disease (CVD) and venous
thromboembolism (VTE), and these vascular complications
have a serious impact on the outcome of patients affected by
autoimmune rheumatic disease.5 Mechanisms involved in
thrombogenesis are varied and remain to be fully understood.
Traditional Framingham cardiovascular risk factors probably
contribute to atherosclerotic process, but they cannot thor-
oughly account for the enhanced risk of thrombotic events in
these patients, and chronic inflammatory activity seems to be
the pivotal risk factor for thrombotic events.6 Accelerated
atherosclerosis, promoted by the persistent inflammatory
activity, is the main feature of several diseases, such as
rheumatoid arthritis (RA)7 and systemic lupus erythematosus
(SLE).8 Arterial thrombosis is the most common manifesta-
tion, and may present as coronary, cerebrovascular, or pe-
ripheral vascular events. VTE, particularly in SLE patients,






Abstract Autoimmune diseases are not infrequently associated with arterial or venous throm-
botic events. Chronic inflammation and immune system impairment are considered the
main pathogenetic mechanisms. Some of the drugs used in the treatment of such
diseases have been associated with an increased risk of thrombosis. On the contrary,
their anti-inflammatory and immune modulator activity could correct some mecha-
nisms leading to thrombosis. In this review, recent evidence available on this topic is
examined. There is a lack of adequate studies, but available evidence suggests that
glucocorticoids and high-dose immunoglobulins are associated with an increased
incidence of venous thromboembolism. Although available data do not allow drawing
definite conclusions and more data are needed from future studies and registries,
physicians should be aware of these associations.
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antibodies.9Urowitz et al10 described themortality pattern in
SLE patients, with an early peak in the first three years after
diagnosis, due to active disease and the degree of organ
involvement. The second peak occurs later, after 4 to 20 years,
and is related to CVD. According to epidemiological data,
nearly all SLE subjects over 65 years develop carotid
plaques.11
Several proinflammatory components of immune system
may act together, thus contributing to the prothrombotic
state and progressive atherosclerotic process. In the arterial
wall of SLE patients, under a chronic inflammatory condition,
an intense inflammatory migration and infiltration of acti-
vated lymphocytes and monocytes has been observed along
with an upregulation of endothelial adhesion molecules, for
example, vascular cell adhesion molecule 1, intercellular
adhesion molecule 1, E-selectin,12,13 and proinflammatory
cytokines, such as interferon (IFN), tumor necrosis factor α
(TNF-α), and interleukin-1 (IL-1).14 High levels of reactive
oxygen species, proinflammatory, and oxidized low-density
lipoproteins and foam cells are also involved in the initiation
and progression of atherosclerosis. Increased endothelial cell
apoptosis and low levels of circulating endothelial progenitor
cells may contribute to vascular damage. Low-density gran-
ulocytes, proinflammatory high-density lipoproteins, neu-
trophil extracellular traps, matrix metalloproteinase,
autoantibodies, such as antiphospholipid antibodies (APL),
anti–oxidized low-density lipoprotein antibodies, and
immune complexes might also trigger thrombogenesis in
SLE patients.15 Similar inflammatory events are involved in
atherosclerosis development process associated with RA,
including T and B cells, proinflammatory cytokines (TNF-α,
IL-1, IL-6, IFN-γ), matrix metalloproteinase, autoantibodies,
proteases, and adipokines (adiponectin, leptin).16
There is strong evidence that thrombotic events may occur
also in systemic vasculitis.17 Both arterial and venous throm-
bosis represent a common vascular manifestation of Behçet
syndrome (BS). Vascular involvement was recently added to
the international criteria for BS.18 Nevertheless, it should be
noted that anti-neutrophil cytoplasmic antibody (ANCA)-
associated vasculitis (AAV) and large-vessel vasculitis (LVV)
have also been associated with an increased susceptibility to
thrombotic complications.19 VTE is the main thrombotic
event in systemic vasculitis, especially during active phases
of disease. Arterial thrombosis is less common, and an
increased risk of CVD has been mostly reported in giant cell
arteritis. The pathophysiology of thrombosis in vasculitis is
poorly known. The cooperation of inflammatory and coagu-
lation pathways has been implicated, with endothelial cell
dysfunction seemingly becoming the prominent feature. The
main mechanisms involved in the cross talk between inflam-
mation and thrombosis in vasculitis include the release of
cytokines (TNF-α, IL-6, IL-1) and chemokines, along with
pathologic activation of leukocytes, neutrophils, endothelial
cells, and platelets. Moreover, most studies have shown
procoagulant endothelial abnormalities such as elevated
levels of tissue factor or enhanced adhesion molecules and
vascular endothelial growth factor expression. Deficiencies of
antithrombin, protein C, and protein S, along with defects in
fibrinolysis, might contribute to the development of
thrombotic events in these patients. Microparticles, neutro-
phil extracellular traps, and antiendothelial cell antibodies
have been described as a possible link between immune
response and endothelial dysfunction in BS as well as in
AAV and LVV17,20
The characteristic feature of thrombotic events in connec-
tive tissue diseases and systemic vasculitis entails deregula-
tion of immune system, with inflammatory activity as the
major risk factor. Here, disease activity control, through anti-
inflammatory therapy, is necessary to prevent and treat
thrombosis in these patients. The European League Against
Rheumatism (EULAR) strategies for prevention and manage-
ment of atherosclerotic disease in RA include immunosup-
pressive agents and an aggressive approach to traditional
cardiovascular risk factors by statins, angiotensin-converting-
enzyme inhibitors, angiotensin-II blockers, and lifestyle
changes.21 Furthermore, EULAR currently suggests immuno-
suppressive drugs as first-line treatment for vascular throm-
bosis in BS patients, and the successful use of anti-TNF-α
antibodies has been increasingly reported, thus underlining
the key role of inflammation in these thrombotic events.22
The beneficial effect of an aggressive immunosuppressive
treatment in the management of thrombotic complications
has been growing over the past years, and it is well known
that treatment of the inflammatory process contributes to
improved thrombotic outcomes in autoimmune diseases.
However, in recent years, the association between throm-
botic events and the administration of antirheumatic drugs
has been observed and several efforts have been made to
elucidate the true value of these observations as well as the
possible pathogenetic mechanisms. The importance of a
correct use of immunosuppressive therapies in autoimmune
disease patients with vascular complications is becoming a
crucial topic. Glucocorticoids, antimalarial drugs, immuno-
suppressive and biologic agents, such as antibody anti-CD20,
TNF blockers, and intravenous immunoglobulin (IVIg) thera-
py are the most important therapeutic options to control
inflammation, but these drugs may also negatively influence
the development of thrombosis. Different mechanisms by
which drugs are able to affect endothelium, coagulation,
blood cells, and blood flow could contribute to thrombosis.
Both venous and arterial thrombosis may occur during
immunosuppressive therapy, but venous involvement is typ-
ically more evident, although several drugs may also enhance
the atherosclerotic process.
The aim of this review is to summarize the available
evidence on thromboembolism incidence and related patho-
genetic mechanisms in autoimmune diseases during the
treatment with the mostly used immunosuppressive drugs.
Glucocorticoids
Glucocorticoids are one of the most frequently prescribed
classes of drugs around the world. It was estimated that 3.5%
of Danish population redeemed a prescription for systemic
glucocorticoids in 2010.23 In the United States, it was esti-
mated that from 1999 to 2008 the prevalence of oral
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glucocorticoid use was 1.2%, and in 28.8% of cases this drug
was used for 5 years and more.24 These products are widely
used in patients with different diseases of various severity,
from autoimmune to neoplastic disorders and pulmonary
diseases.
It has been long known that glucocorticoids (mainly above
7.5 mg/daily) are associated with an increased risk of high
cholesterol levels, hyperglycemia, hypertension, and Cushing
syndrome (CS), thus promoting atherosclerosis and arterial
complications. Moreover, some studies have pointed out an
association between glucocorticoid use and thromboembolic
events.25,26
A multicenter case-control study performed in the
Netherlands reported an incidence rate of 14.6 per 1,000
person-years of thromboembolic events in patients with
endogenous CS. Moreover, these subjects were compared
with those diagnosed with nonfunctioning pituitary adeno-
ma, and both groups were treated with transsphenoidal
surgery. It was found that the risk of postoperative thrombo-
embolism was significantly greater in subjects with endoge-
nous hypercortisolism that in controls.27
However, for exogenous glucocorticoids, data on the risk
for developing thrombotic complications are sparse, and the
population studied is heterogeneous and with multiple
comorbidities.
In a population-based case-control study using Danish
databases, Johannesdottir et al28 reported that new or pres-
ent glucocorticoid users have an increased risk of VTE. The
adjusted incidence rate ratio (IRR) of VTEwas 3.06 and 2.31 in
present and new users, respectively. Subjects who filled their
most recent glucocorticoid prescriptionwithin 91 to 365 days
before the index date had an IRR of 1.18, whereas in former
users it was 0.94 and was not associated with VTE. The effect
was strongest for new users of systemic glucocorticoids, but
persisted among users of inhaled glucocorticoids and gluco-
corticoids acting on the intestine. The adjusted IRR increased
directly with the prednisolone-equivalent cumulative dose
used, reaching 1.60 for doses higher than 2 g.
Asthma,29 hematological malignancies (e.g., acute leuke-
mia,30 multiple myeloma31,32), and inflammatory bowel dis-
eases (IBDs),33–35 all conditions with a relevant systemic
inflammation, are characterized by an important thrombo-
embolic risk, and all the available clinical studies found that
corticosteroids use may increase this risk.36
Similar results were found in subjects undergoing solid
organ transplantation. Up to 34% of patients undergoing solid
organ transplantation may develop VTE, even if percentages
vary widely (renal transplantation: 2–14%; liver transplanta-
tion: 3–5%; heart transplantation: 18–34%; lung transplanta-
tion: 8–29%).37 Coagulation and fibrinolysis appeared to be
impaired in kidney recipients, and Patrassi et al found that
steroid use mainly determined the thromboembolic risk in
these subjects.38 These subjects had increased plasminogen
activator inhibitor 1 (PAI-1) levels, which normalized after
steroids withdrawal. Impaired fibrinolysis was found in 83%
of kidney recipients, but dropped to 16.7% when steroids
were stopped.39
Glucocorticoids are also used in autoimmune diseases,
which have an increased thromboembolic risk per se, as
previously described.40,41
In the Hopkins Cohort study, the risk of developing any
new organ damage in SLE patients was found to be indepen-
dently associated with prednisone use, and the risk wasmore
than doubled if subjects were exposed to amean dose of20|
mg/day compared with a mean dose of <7.5|mg/day (hazard
ratio [HR] ¼ 2.514; p < 0.001). The risk of developing cardio-
vascular damage increases with a mean prior prednisone
dose of 7.5|mg/day versus <7.5|mg/day (HR ¼ 1.54;
p ¼ 0.041).42 Previous studies found similar data,43 and
high-dose corticosteroid use was also associated with CVD
in SLE.44
Mainly invitro but also clinical studies demonstrated that in
CS all components of the coagulation system are variously
impaired (►Fig. 1). Fibrinolytic activity is involved as decreas-
ing levels of fibrinogen and plasminogen and increased con-
centrations of PAI-1 were found in in vitro, animal, and human
studies.45–50 On the other hand, increased levels of prothrom-
bin, antithrombin, von Willebrand factor, factor VIII, factor IX,
factor XI, and factor XII were reported in CS patients.51–53
Glucocorticoids act also in the control of vascular smooth
muscle tone, by inducing an imbalance between vasoconstric-
tion and vasodilatation.
Vasoconstriction is mediated by impaired regulation of
production and secretion of various mediators, along with
increased sensitivity and reactivity of tissues to their action.54
The synthesis and secretion of endothelin-1 is increased by
glucocorticoid administration.55,56 Hypertensive rats treated
with subcutaneous injections of dexamethasone have an
increased production of catecholamines, and similar results
were found in other animal models as well as in human
studies.57,58 Other vasoactive substances are also excessively
produced, such as neuropeptide Y, arginine, vasopressin,
atrial natriuretic peptide, and angiotensinogen.57,59 Vaso-
dilatory substances, conversely, are negatively regulated by
glucocorticoids. The nitric oxide biosynthetic pathways are
influenced by glucocorticoids, leading to nitric oxide defi-
ciency. Also, prostacyclin, prostaglandin E2, and kallikrein
production and activity are impaired.60
As a result of the vascular wall architecture impairment, a
high prevalence of atherosclerotic plaques, increased stiff-
ness, and intima-media thickness were demonstrated in CS
subjects.25
Moreover, the hypercoagulability in CS was recently
investigated using the thrombin generation test.61 CS sub-
jects were compared not only with healthy controls, but
alsowith patients diagnosedwithmetabolic syndrome. It is
interesting to note that the authors concluded that the
thrombin generation test confirmed the presence of im-
paired coagulation in CS, but results are similar to those
obtained in subjects with the metabolic syndrome. This
underlines the importance of other factors such as obesity,
hypertension, and diabetes (typically related to hypercor-
tisolism and dysmetabolism) in determining the overall
thrombotic risk.
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The first case-report of a thromboembolic complication in a
patient treated with IVIg was published in the 1980s.62 Over
the last decades, several authors investigated the incidence of
thrombotic events in subjects treatedwith immunoglobulins,
but available studies are heterogeneous and mainly retro-
spective, and the populations studied vary widely. Moreover,
another possible confounder is that from recent years im-
munoglobulins may be administered also via the subcutane-
ous route,63 and most recent studies include subjects treated
with these preparations. The main findings in the literature
on this topic are shown in ►Table 1.64–74 Despite the incon-
clusive evidence, in 2002 the U.S. Food and Drug Administra-
tion required an updated package labeling for Ig to include a
warning about the risk of thrombotic events.75
Taking into account these limitations, the reported inci-
dence of thrombotic events varies from 3 to 13%.65,76 These
events are more frequent within 24 hours after the infusion,
and decrease with time. Caress et al,77 in a 4-year follow-up,
analyzed a total of 498 IVIg prescriptions. Of these, 16
patients developed a stroke event, with an incidence of
0.6%, within 4 days after the infusion, and in 88% of cases
within 24 hours. Data from two registries69,71 supported the
prothrombotic role of IVIg.
Thromboembolic events, both arterial and venous, occur
more frequently in subjects with cardiovascular risk factors
such as hypertension, hyperlipidemia, coronary artery dis-
ease, and diabetes mellitus.78 Rajabally and Kearney67 corre-
lated the high incidence of early thromboembolic events with
cardiovascular risk factors. In a recent case-control study, the
thromboembolic risk was elevated when two or more car-
diovascular risk factors were present.66 Comorbidity with
hospitalization and advanced age are all factors that may
increase the incidence of thrombotic events in IVIg-treated
subjects66,67
Ramírez et al72 reported that also the indication for IVIg
therapy may influence the thrombotic risk. Specifically, neuro-
logic and autoimmunediseasepatients seem tobemore affected
comparedwith otherdiseases such asprimary immunodeficien-
cy syndrome and immune mediated thrombocytopenia.
Finally, the method of administration may influence the
outcome. Even if comparable risks in IVIg-naïve and previ-
ously IVIg-exposed patients were found, a greater risk for a
first-ever course administeredwas also noted, and high doses
(over 35 g/day)may increase the thromboembolic risk.67,68,72
On the other hand, some authors reported contrasting
data.79 The Quebec Hemovigilance System performed a ret-
rospective review of all registered thrombosis cases in IVIg-
treated patients. There were eight cases of IVIg-related
thrombosis during 11 years of follow-up, with a prevalence
of 0.06 cases per 100,000 g of IVIg given. Thus, in this
population, thrombosis was not a frequent complication of
IVIg therapy.74
IVIg are sometimes used in SLE and in antiphospholipid
syndrome (APS) treatment. APS is a condition in which the
presence of antiphospholipid antibodies is related to devel-
opment of arterial and venous thromboses, and it may affect
subjects with or without other autoimmune disease, particu-
larly SLE.80 It seems that IVIgmay reduce themortality rate in
Fig. 1 Main prothrombotic mechanisms of glucocorticoids. ": increased;↓: reduced; AT: antithrombin; VWF: von Willebrand factor; FVIII: factor
VIII; FXI: factor XI; FXII: factor XII; PAI-1: plasminogen activator inhibitor-1.
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Table 1 Main findings in studies evaluating risk factors for thromboembolic events in subjects treated with immunoglobulins
Authors, year, and type of study Population studied and
follow-up
Main findings
Paran et al,64 2005, retrospective
cohort and literature review
Cohort: Six subjects that
developed TE after IVIg,
NR follow-up
Review: 65 cases of post-
IVIg TE
Cohort: Six TEs (four DVTs, two SVTs).
Review: 36 strokes, 13 MIs, 1 stroke/MI, 1 limb ischemia, 12
DVTs/PEs, 1 CVRT, 1 CSVT. Reported incidence of post-IVIg TE:
0.6 to 3%. Mortality: 20%.
Patients with venous thrombosis were younger than those
with arterial thrombosis.
Risk factors: advanced age, hypertension, and coronary artery
disease.
Arterial events occurred early (within 24 h), venous events
occurred later (after 24 h)
Marie et al,65 2006, retrospective
cohort
46 subjects treated with
IVIg,
2-y follow-up (2002–2004)
Six TEs (three DVTs/PEs, two MIs, one stroke).
50% of TE occur during IVIg infusion and 50% within 1 to 8 d.
Risk factors: older age, hypertension, and
hypercholesterolemia
Caress et al,66 2009, retrospective
case control
19 TE compared with 38
non-TE in subjects treated
with IVIg,
6-y follow-up (1998–2004)
19 TEs (12 strokes, 3 MIs, 2 strokes and MIs, 1 MI and DVT, 1
PE).
Presence of four CV risk factors significantly increased TE risk.
Elderly and hospitalized patients are at increased risk of TE and
30-d mortality
Rajabally and Kearney,67 2011,
retrospective cohort
62 subjects with neuroim-
mune diseases,
2-y follow-up (2008–2010)
Seven TEs (two MIs, one ACS, one DVT/PE, one DVT).
Five of seven patients developed TE within 14 days, similar
incidence in naïve versus previously treated subjects.
Risk factors for early TE: high IVIg doses (35 g), immobility,
and presence of four or more CV risk factors
Huang et al,68 2011,
retrospective case control
67 and 22 renal recipients
with antibody-mediated
rejections receiving two
different IVIg infusion pro-
tocols,
5-y follow-up (2005–2010)
for old protocol, 6 months
for newer protocol
Old protocol: Nine TEs (one NSTEMI, one RAT, one DVT, six
CAVFs) (77.8% occurred within 24 h).
Newer protocol: no TE occurred (hydration pre- and post-IVIg;
routine enoxaparin and aspirin preinfusion; maximal infusion
rate of 100 mg/kg/h)
Daniel et al,69 2012, retrospective
cohort (database)
11,785 subjects treated
with IVIg or SCIg,
2-y follow-up (2008–2010)
122 same-day TEs (35 arterial, 84 venous, 3 arterial and
venous) (I: 10.4 per 1,000 subjects)
Vivaglobin (SCIg) had a significant increased same-day TE risk if
compared with the reference IVIg product.
Increased TE risk was also observed with older age (45 y),
prior TE events, and hypercoagulable state
Funk et al,70 2013, retrospective
cohort
198 TE subjects
treated with IVIg or SCIg,
6-y follow-up (2006–2011)
183 IVIg TEs, of these 100 occurring within 48 h after the
infusion (45 strokes, 24 MIs, 18 PEs, 17 VTEs).
29 SCIg TEs, 10 occurring within 48 h (6 strokes, 3 VTEs, 1
MIs).
Overall mortality: 32%.
Risk factors: elderly, men, comorbid conditions, high doses,
and diuretics use.
During the follow-up period, TE incidence increased for Oc-
tagam and Vivaglobin.
Measuring NAPTT and TGA, an increased procoagulant was
demonstrated for Octagam and Vivaglobin. After changes in
the manufacturing process, the TE events rate decreased
significantly for Octagam






Risk factors: age 45 y and over, hypercoagulable states,
history of TE, and use of products with elevated factor IX
activity
Ramírez et al,72 2014,
retrospective cohort
303 subjects treated with
IVIg,
2-y follow-up (2008–2010)
50 TEs (8 MIs, 5 strokes, 5 CRAs, 4 CSs, 3 AAIs, 2 TIAs, 11 DVTs,
7 PEs, 3 IVCTs) (I: 16.9%).
Risk factors: atrial fibrillation, coronary disease, diabetes,
dyslipidemia, hypertension, immobility, neoplasia, recent
(Continued)
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catastrophic APS, a rare complication of APS with multiple,
life-threatening thromboses.81
It was also observed that high dose of IVIg infusion may
impair platelet function as suggested in in vitro aggregometry
studies.62,82 A recent study83 found that IVIg could influence
platelet and monocyte activation via the ADP and TRAP-6-
elicited response. IVIg, particularly those associated with
increased incidence of thromboembolic events, can impair
FcγRII-dependent tissue factor expression in monocytes.
Moreover, IVIg enhance platelet aggregation, as all IVIg lots
studied contain CD154-related proteins.
IVIg can have impact on another component of the
Virchow triad, that is, the vascular wall. Actually, IVIg in-
creases blood viscosity,84,85 and seems to be able to induce
arterial vasospasm86 and endothelial damage.87
Another question is about the manufacturing processes of
IVIg preparations, which may contain substances with a high
prothrombotic potential. High levels of anticardiolipin/anti-
phospholipid antibodies were found in some preparations,
which could promote a thrombotic event via the develop-
ment of APS.88Wolberg et al88 and Etscheid et al89 also found
the presence of factor XIa and kallikrein in IVIg preparations.
The modification of manufacturing processes and thrombo-
genicity testing before the release for clinical use can improve
the safety of IVIg preparations, as seen for some products such
as Octagam and Vivaglobin.70,90
Monoclonal Antibodies
To date, monoclonal antibodies are used in a wide range of
autoimmune diseases. In a recent cohort study, that the riskof
thromboembolism was found to be low in newly diagnosed
RA patients, but the initiation of a therapy with monoclonal
antibodies was associated with an increased short-term risk
(first 180 days of follow-up), compared with disease-modify-
ing antirheumatic drugs (DMARDS).91
Rituximab, a monoclonal anti-CD20 antibody, is used for
the treatment of some oncohematological disorders such as
chronic lymphocytic leukemia, low-grade or follicular lym-
phoma, and diffuse large B-cell lymphoma.92 Its immuno-
modulatory activity led to its use in some autoimmune
diseases (RA, vasculitis, SLE, etc.).93 In some case reports,
cardiac adverse events were correlated with rituximab infu-
sion for oncohematological disorders, in combination with
other chemotherapeutic agents.94,95 Similar data were found
for autoimmune diseases,96,97 even if, recently, a large cohort
study found that rates of cardiac (and stroke) events in RA
subjects treated with rituximab were consistent with rates
found in general RA population in an 11-year follow-up.98
Another monoclonal antibody used in RA is tocilizumab,
an anti-IL-6 receptor antibody. To summarize data on the
efficacy and safety of tocilizumab in RA, a recent systematic
review focused on clinical studies from January 1989 to
August 2011.99 IL-6 is an important proinflammatory cyto-
kine, involved in the pathogenesis of most systemic inflam-
matory diseases and also in atherosclerosis100 and coronary
heart disease.101 No venous or arterial thrombotic event was
reported in trials, whereas an increased level of plasma lipids
was reported, even if it was reversible after an adequate lipid-
lowering therapy. A recent study by Ringelstein et al102
confirmed the possible role of tocilizumab impairing lipid
metabolism. On a population of eight patients affected by
Table 1 (Continued)
Authors, year, and type of study Population studied and
follow-up
Main findings
surgery, SOT, and the presence of four or more CV risk factors.
Co-medication with diuretics, immunosuppressants, mono-
clonal antibodies, and prepared hematinics was significantly
more frequent in TE patients.
Arterial TE occurred after a median of 1 d (0–20) after the
infusion, venous after 10 d (0–27)
Sridhar et al,73 2014,
retrospective cohort (database)
14,944 subjects treated
with IVIg or SCIg,
5-y follow-up (2008–2012)
233 (15.6 per 1,000 persons) had same-day TE (71 were
arterial, 157 were venous, and 5 had both).
Same-day TE rates varied for different Ig products ranging
from 0.7% for Hizentra and up to 14.3% for Gammaplex. An
increased TE risk was found with older age (45 y), prior TEs,
lymphoma, pulmonary circulation disorders, alcohol abuse,
and hypercoagulable state
Benadiba et al,74 2015,
retrospective cohort (database)




Eight TE (three strokes, two PEs, one CSV, two DVTs).
The overall adult and pediatric TE rates were 0.064, 0.059, and
0.168 per 100,000 g of IVIg given, respectively
Abbreviations: AAI, acute arterial ischemia; ACS, acute coronary syndrome; CAVF, clotted arteriovenous fistula; CRA, cardiorespiratory arrest; CS,
cardiogenic shock; CSVT, cerebral sinus vein thrombosis; CV, cardiovascular; CVRT, central vein retinal thrombosis; DVT, deep vein thrombosis;
I, incidence; IG, immunoglobulin; IVCT, inferior vena caval thrombosis; IVIg, intravenous immunoglobulin; MI, myocardial infarction; NAPTT,
nonactivated partial thromboplastin time; NR, not reported; NSTEMI, non-ST-elevation MI; PE, pulmonary embolism; RAT, renal artery thrombosis;
SCIg, subcutaneous immunoglobulin; SOT, solid organ transplantation; SVT, superficial vein thrombosis; TE, thromboembolic event; TGA, thrombin
generation assay; TIA, transient ischemic attack.
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active neuromyelitis optica spectrum disorder, only one
developed deep vein thrombosis (DVT); however, a moderate
cholesterol elevation has been observed in six of these
patients.
Adalimumab, etanercept, and infliximab are themost used
anti-TNF-α antibodies in autoimmune disorders. They were
tested in psoriasis, RA, IBD, spondyloarthropathies, and vas-
culitis. The rationale of their use in these diseases is that TNF-
α is one of the main actors in the inflammatory cascade,
initiating proinflammatory genes transcription, inducing
leuko-endothelial adhesion and infiltration, and contributing
to the endothelial damage.103,104On this basis, the anti-TNF-α
therapy should have a protective effect for the development
of a thromboembolic event.
Soluble and surface CD40 ligand is overexpressed in Crohn
disease, and via the modulation of CD40/CD40 ligand path-
way, infliximab seems to improve the interaction between T-
lymphocytes and vessel walls and platelet activation.105
Moreover, infliximab normalizes the fibrinolytic activity, as
seen in studies where it decreased the levels of prothrombin
fragment 1 þ 2 and D-dimer,106 PAI-1, and tissue-type plas-
minogen activator, and improved PAI-1 activity,107,108 thus
normalizing clot lysis profile.109 A recent prospective obser-
vational cohort safety study in patients with RA showed that
anti-TNF-α therapy is not related to any increase in the
incidence of VTE events.110 Moreover, Di Minno et al111
performed a case-control study where anti-TNF-α therapy
was compared with traditional DMARDS treatment in psori-
atic arthritis. They found that TNF-α inhibitors significantly
improved the hemostatic and fibrinolytic balance compared
with DMARDS. In several case reports, thrombotic complica-
tions in BS, a variable vessel vasculitis with a high thrombotic
risk, were successfully treated with TNF-α inhibitors.112–114
On the other hand, several authors reported that during
anti-TNF-α therapy the production of autoantibodies,115 or the
increase in thewhite blood count and IgG index (as seen in the
spinal fluid of patients with multiple sclerosis treated with
humanized mouse monoclonal anti-TNF-αantibody),116 may
lead to increased viscosity. Moreover, antiphospholipid anti-
bodies have been found during anti-TNF-α therapy and some-
times are associated with the development of APS.117–121
Disease-Modifying Antirheumatic Drugs
DMARDS are extensively used in different autoimmune rheu-
matic diseases, such as SLE and RA among them. Despite the
different mechanisms of action, these drugs can reduce
systemic inflammation.
With increasing interest on the role of inflammation in the
pathogenesis of atherosclerotic CVD, some clinical studies
assessed the potential role of anti-inflammatory agents for
preventing plaque formation and progression.122 The Cardio-
vascular Inflammation Reduction Trial evaluates the use of
low-dose methotrexate in patients with chronic atheroscle-
rosis and diabetes mellitus or metabolic syndrome in relation
to its capability to reduce the incidence of major cardiovas-
cular events; results are expected in 2018. VTE episodes were
reported during methotrexate use, especially in chemothera-
py regimens. On the other hand, when used in RA subjects,
methotrexate seems to be protective against thromboembolic
events.91
Recently, Belizna123 reported data on the antithrombotic
activity of hydroxychloroquine in APS. This drug has anti-
platelet effects and inhibits antiphospholipid antibodies
binding to phospholipids surfaces. Some clinical studies
confirmed that in SLE and in primary and secondary APS
hydroxychloroquine can reduce the incidence of thrombotic
events.124,125
DVT has been reported during azathioprine use, but to
date in only 0.55% of cases.126On the other hand, azathioprine
and its active metabolite 6-mercaptopurine are involved in
the induction of warfarin resistance, as reported in some case
reports.127 Pushpakom et al128 described a case of recurrent
thrombosis and pulmonary embolism in a man with Crohn
disease during warfarin treatment. In this case, the patient
had a severe genetically determined warfarin resistance
(Val66Met substitution in vitamin K epoxide reductase com-
plex subunit 1) and international normalized ratio increased
after azathioprine cessation, suggesting that this drug can
have a prothrombotic effect also by interfering with warfarin
metabolism.
Cyclosporine, an immunosuppressive agent that can also
induce changes in endothelial cell metabolism, is involved in
the pathogenesis of thrombotic microangiopathies, such as
thrombotic thrombocytopenic purpura (TTP), via a dose-related
direct toxicity.129–132 Indeed, cyclosporine usewas related to the
occurrence of nephrotoxicity and hypertension.133 Studies from
our group found, and successively confirmed, that the use of
cyclosporine in renal transplant is associatedwith increased risk
of first event and recurrent VTE, both symptomatic and asymp-
tomatic.134–136 In addition, thrombosis of graft vessels after
simultaneous pancreas and kidney transplantation seems to
be less frequent when cyclosporine was replaced with tacroli-
mus in the immunosuppressive protocol.137
In vivo studies showed that subjects assuming cyclospor-
inemay have an increased risk of developing VTE, particularly
DVT and pulmonary embolism.138
This drug seems to activate coagulation system, because it
leads to dose-dependent exposure of subendothelial ma-
trix.139 Cyclosporine accelerates microvascular thrombus for-
mation in vivo and it increases oxidative stress in
experimental animals.140 Moreover, it leads to generation
of reactive oxygen species, measured as the activities of
antioxidative enzymes glutathione peroxidase, catalase, su-
peroxide dismutase, or as malonyldialdehyde concentrations
in rats.141 Platelet aggregation/secretion and thromboxane
A2 release are also impaired by cyclosporine, and also coagu-
lation and fibrinolytic systemsmay be involved. Cyclosporine,
in combination with methotrexate and fluorouracil, de-
creases the levels of anticoagulant proteins C and S and
increases PAI-1.142,143
In 2006, a review by Haddad and Greeno144 focused on the
possible link between chemotherapeutic agents and throm-
boembolism. Cyclophosphamide is used in various chemo-
therapy regimens, and in the last decades, its use has been
reported to be associatedwith an increased riskof VTE.145–149
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Notably, it is difficult to determine the mechanism of this
increase. However, cyclophosphamide was found to have a
procoagulant activity in animal studies. Actually, thrombin
generation is increased when acrolein, a cytochrome P me-
tabolite, impairs the phosphatidylserine exposure and tissue
factor activity. In the same study, mice treated with cyclo-
phosphamide and acrolein had elevated plasma thrombin/
antithrombin complex levels, whereas anticoagulant protein
C levels remained low.150 This drug is able to modify the
microvascular architecture causing endothelial damage,151 as
shown in an experimental model on liver specimens, result-
ing in blood stasis and thrombosis.152
In human studies, cardiotoxicity has been reported in
patients treated with cyclophosphamide, and the association
withmethotrexate and fluorouracil chemotherapymay cause
protein C and protein S deficiency along with enhanced PAI-1
levels.153
However, the majority of studies that found a prothrom-
botic activity of cyclophosphamide are based on subjects with
oncohematological diseases, often in combination with other
immunosuppressive drugs and with other prothombotic risk
factors.
Cyclophosphamide is a milestone in the treatment of
autoimmune diseases and several case reports found that it
might be useful in the prevention of recurrent thrombotic
events in these patients.154–158
Conclusion
Different systemic autoimmune diseases are complicated by
thrombotic events.1 Early atherosclerosis occurs particularly
in SLE and RA, whereas both arterial and venous thrombosis
are often seen in systemic vasculitis.17 BS is a typical example,
as it is often complicated by the occurrence of thrombotic
events.159 Immunosuppressive drugs are a cornerstone in the
treatment of these conditions, but, even if there is some
conflicting evidence, they can impair one or more compo-
nents of the Virchow triad with different mechanisms. Ac-
cording to the EULAR recommendations, immunosuppressive
agents represent the first choice for treatment of inflamma-
tion in autoimmune diseases, and the suppression of the
underlying inflammatory process might contribute to pre-
vent thrombotic events.21 Some observational studies and
case reports have reported vascular complications associated
with immunosuppressive therapies. These drugs, paradoxi-
cally, may have effects on procoagulant and fibrinolytic
factors, endothelium, platelet activity, and blood flow, thus
leading to enhanced thrombogenesis.
To date, more evidence is available on the glucocorticoid
use, as they are involved in atherosclerotic plaque formation
and progression, coagulation function impairment, endothe-
lial damage, and vascular wall dysfunction. More conflicting
and partial data can be found for other drugs, such as
monoclonal antibodies, endovenous immunoglobulins, and
DMARDS. High-dose IVIg may also be related to thrombosis.
It is difficult, to date, to establish the clinical relevance of
the prothrombotic potential of each immunomodulant drug
and, above all, how physicians should choose the better
immunomodulant regimen. Additional research is needed
to better elucidate the mechanisms of the prothrombotic
activity of these treatments, and further challenges will be
required to identify the real impact of immunosuppressive
agents in the onset of thrombotic events in patients with
autoimmune diseases and systemic vasculitis. In the mean-
time, physicians should be aware of these potential risks.
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